In addition, Potus et al. [49] identified differential genes in rats with pulmonary arterial hypertension and right ventricular failure in 2018, and identified a related dysregulated gene ANXA1, which was presumed to be a potential target for the treatment of pulmonary hypertension with right ventricular failure (RVF–PAH). This evidence concerns the gene ANXA1 and pulmonary arterial hypertension.